EUCTR2018-002526-23-LT进行中（未招募）1 期
A Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter baumannii-calcoaceticus Complex
Entasis Therapeutics0 个研究点目标入组 228 人开始时间: 2019年3月29日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 228
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •General Inclusion Criteria for Part A and B:
- •1. A signed informed consent form (ICF); Note: If a study patient is unable to provide informed consent due to their medical condition, the patient’s legally authorized representative may consent on behalf of the study patient, or the decision can be made according to the procedure permitted by local law and institutional Standard Operating Procedures in compliance with the protocol;
- •2. Male or female 18 years of age or older;
- •3. A confirmed diagnosis of a serious infection and the expectation, in the judgment of the Investigator, that the patient’s infection will require treatment with intravenous (IV) antibiotics;
- •4. A known infection caused by ABC (bacteremia, HABP, VABP, VP, cUTI or AP, or surgical or post traumatic wound infections) as either a single pathogen or member of a polymicrobial infection based on evidence from culture or, if available, rapid diagnostic test from a sample collected within 72 hours prior to randomization (HABP/VABP/VP patients), AND 1 of the following:
- •a. Has received no more than 48 hours of potentially effective (i.e. Gram negative coverage) antimicrobial therapy prior to enrollment; OR
- •b. Is clinically failing prior treatment regimens (i.e., clinical deterioration or failure to improve after at least 48 hours of antibiotic treatment);
- •5. APACHE II score between 10 and 30, inclusive, OR SOFA score between 7 and 11, inclusive, at the time of diagnosis of infection. Patients who are not being treated in an intensive care unit and cannot have an APACHE II or SOFA score performed should have a SOFA score more/equal 2 for enrollment;
- •6. Expectation, in the judgment of the Investigator, that the patient will benefit from effective antibiotic therapy and appropriate supportive care
- •for the anticipated duration of the study; and
- •Women of childbearing potential (i.e., not post-menopausal or surgically sterilized) must have highly sensitive urine or serum pregnancy test before randomization. Participating women of childbearing potential must be willing to consistently use one highly effective method of contraception (ie, condom, combined oral contraceptive, implant, injectable, indwelling intrauterine device, or a vasectomized partner) from Screening until at least 30 days after administration of the last dose of study drug;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 118
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 110
排除标准
- •1. Presence of suspected or confirmed deep-seated infection (eg, lung abscess in patients with pneumonia, skin abscess, or decubitus ulcer)
- •that is not planned on being drained or debrided within 24 hours after randomization;
- •2. Evidence of active concurrent pneumonia requiring additional antimicrobial treatment caused by e.g. Streptococcus pneumoniae, Haemophilus influenzae, etc;
- •3. Pulmonary disease that precludes evaluation of a therapeutic response (such as lung cancer resulting in bronchial obstruction or on the same
- •side as the pneumonia, active tuberculosis, cystic fibrosis, granulomatous disease, fungal pulmonary infection, lung abscess, pleural empyema, post obstructive pneumonia or COVID-19 infection without clinical improvement);
- •4. Presence of suspected or confirmed deep seated bacterial infections such as bacterial Gram negative osteomyelitis, endocarditis, or meningitis requiring prolonged therapy, as determined by history and/or physical examination;
- •5. Acute infective endocarditis due to Gram positive bacteria that require urgent/emergent indication of surgery (ie, heart failure because of valvular insufficiency or septic shock), or patients in whom surgery is contraindicated due to prohibitive risk for surgery due to comorbidities;
- •6. Irremovable implantable device or line thought to be the potential source of ABC infection;
- •7. Sustained shock with persisting hypotension requiring vasopressors to maintain mean arterial pressure (MAP) above/equal to 60 mmHg;
- •8. For patients to be enrolled with the primary indication of HABP, VABP or VP any of the following conditions:
- •a. Diagnosis of ventilator-associated tracheobronchitis; or
- •b. Inability to provide proper respiratory specimens for culture. Respiratory samples from expectorated or induced sputum should show <10 squamous epithelial cells and >25 polymorphonuclear neutrophils per 100 field;
- •9. For patients to be enrolled with the primary indication of cUTI or AP, any of the following urologic conditions:
- •a. Likely to receive ongoing antibacterial drug prophylaxis after treatment of cUTI (eg, patients with vesico-uretal reflux);
- •b. Suspected or confirmed prostatitis;
- •c. Requirement for bladder irrigation with antibiotics or for antibiotics to be administered directly via urinary catheter;
- •d. Previous or planned cystectomy or ileal loop surgery;
- •e. Uncomplicated urinary tract infection (eg, female patients with urinary frequency, urgency, or pain or discomfort without systemic symptoms or signs of infection);
- •f. Complete, permanent obstruction of the urinary tract;
- •g. Suspected or confirmed perinephric or renal corticomedullary abscess;
- •h. Polycystic kidney disease; or
- •i. Any recent history of trauma to the pelvis or urinary tract;
- •10. Pregnant or breastfeeding women;
- •11. APACHE II score >30 and SOFA score > 11 at the time of diagnosis of infection;
- •12.Receiving peritoneal dialysis;
- •13. Requirement for temporary or acute onset treatment with antiseizure medication that, in the opinion of the Investigator, would prohibit the patient from complying with the protocol. Patients at risk of seizure or requiring prophylactic antiseizure medications during the study can be considered for enrollment at the discretion of the Investigator. Patients with a history of epilepsy or who are on stable treatment (ie, no recurrent episodes in the past 30 days) and no history of imipenem-associated seizures may be considered for enrollment in the study;
- •14. Requirement for continuing treatme
研究者
相似试验
尚未招募
3 期
Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter baumannii-calcoaceticus ComplexCTRI/2019/07/020401Entasis Therapeutics
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Efficacy and Safety of Sulbactam-ETX2514, a New Drug in the Treatment of Patients With ABC Infections Caused by Acinetobacter baumannii-calcoaceticus ComplexInfections Caused by Acinetobacter baumannii-calcoaceticus ComplexMedDRA version: 20.0 Level: LLT Classification code 10003999 Term: Bacteremia System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0 Level: HLT Classification code 10046577 Term: Urinary tract infections System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1 Level: PT Classification code 10037597 Term: Pyelonephritis acute System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0 Level: LLT Classification code 10076918 Term: Hospital acquired pneumonia System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1 Level: LLT Classification code 10065153 Term: Ventilator associated pneumonia System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0 Level: LLT Classification code 10078408 Term: Surgical site infection System Organ Class: 10021881 - Infections and infestationsEUCTR2018-002526-23-GREntasis Therapeutics246
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Efficacy and Safety of Sulbactam-ETX2514, a New Drug in the Treatment of Patients With ABC Infections Caused by Acinetobacter baumannii-calcoaceticus ComplexInfections Caused by Acinetobacter baumannii-calcoaceticus ComplexMedDRA version: 20.0Level: LLTClassification code 10003999Term: BacteremiaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10076918Term: Hospital acquired pneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10065153Term: Ventilator associated pneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10078408Term: Surgical site infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-002526-23-HUEntasis Therapeutics308
尚未招募
3 期
Clinical trial ofstress and Sleep management supplementCTRI/2024/07/070701ife Synergy
招募中
不适用
RANDOMIZED, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS SULBACTAM-ETX2514 IN THE TREATMENT OF PATIENTS WITH INFECTIONS CAUSED BY ACINETOBACTER BAUMANNII-CALCOACETICUS COMPLEX-J181 Lobar pneumonia, unspecified-A415 Sepsis due to other Gram-negative organismsSepsis due to other Gram-negative organismsLobar pneumonia, unspecifiedA415J181PER-011-19ENTASIS THERAPEUTICS, INC,24